Literature DB >> 21604822

Cost-of-illness studies: a guide to critical evaluation.

Allison Larg1, John R Moss.   

Abstract

Cost-of-illness (COI) studies aim to assess the economic burden of health problems on the population overall, and they are conducted for an ever widening range of health conditions and geographical settings. While they attract much interest from public health advocates and healthcare policy makers, inconsistencies in the way in which they are conducted and a lack of transparency in reporting have made interpretation difficult, and have ostensibly limited their usefulness. Yet there is surprisingly little in the literature to assist the non-expert in critically evaluating these studies. This article aims to provide non-expert readers with a straightforward guide to understanding and evaluating traditional COI studies. The intention is to equip a general audience with an understanding of the most important issues that influence the validity of a COI study, and the ability to recognize the most common limitations in such work.

Entities:  

Mesh:

Year:  2011        PMID: 21604822     DOI: 10.2165/11588380-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  90 in total

1.  Evaluating the tobacco settlement damage awards: too much or not enough?

Authors:  Maribeth Coller; Glenn W Harrison; Melayne Morgan McInnes
Journal:  Am J Public Health       Date:  2002-06       Impact factor: 9.308

Review 2.  The economic cost of epilepsy: a review of the literature.

Authors:  Charles E Begley; Ettore Beghi
Journal:  Epilepsia       Date:  2002       Impact factor: 5.864

3.  Methods of calculating deaths attributable to obesity.

Authors:  Katherine M Flegal; Barry I Graubard; David F Williamson
Journal:  Am J Epidemiol       Date:  2004-08-15       Impact factor: 4.897

4.  Prevalence-based economic evaluation.

Authors:  J Mauskopf
Journal:  Value Health       Date:  1998-11       Impact factor: 5.725

Review 5.  Economic costs of drug abuse: financial, cost of illness, and services.

Authors:  William S Cartwright
Journal:  J Subst Abuse Treat       Date:  2007-06-27

6.  The cost of diabetes. A useful statistic?

Authors:  C Donaldson; K M Narayan
Journal:  Diabetes Care       Date:  1998-08       Impact factor: 19.112

7.  Cost-of-illness methodology: a guide to current practices and procedures.

Authors:  T A Hodgson; M R Meiners
Journal:  Milbank Mem Fund Q Health Soc       Date:  1982

8.  The direct health care costs of obesity in the United States.

Authors:  D B Allison; R Zannolli; K M Narayan
Journal:  Am J Public Health       Date:  1999-08       Impact factor: 9.308

9.  Estimating the cost of illness.

Authors:  D P Rice
Journal:  Am J Public Health Nations Health       Date:  1967-03

10.  The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action.

Authors:  Wanda Bemelmans; Pieter van Baal; Wanda Wendel-Vos; Jantine Schuit; Edith Feskens; Andre Ament; Rudolf Hoogenveen
Journal:  Prev Med       Date:  2007-08-03       Impact factor: 4.018

View more
  108 in total

Review 1.  Cost-of-Illness Studies: An Updated Review of Current Methods.

Authors:  Eberechukwu Onukwugha; Jacquelyn McRae; Alex Kravetz; Stefan Varga; Rahul Khairnar; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

Review 2.  Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases.

Authors:  Natalie McCormick; Carlo A Marra; J Antonio Aviña-Zubieta
Journal:  Curr Rheumatol Rep       Date:  2017-10-30       Impact factor: 4.592

3.  Quality of life, resource use, and costs related to hip fracture in Estonia.

Authors:  M Jürisson; H Pisarev; J Kanis; F Borgström; A Svedbom; R Kallikorm; M Lember; A Uusküla
Journal:  Osteoporos Int       Date:  2016-02-23       Impact factor: 4.507

Review 4.  The economic impact of Clostridium difficile infection: a systematic review.

Authors:  Natasha Nanwa; Tetyana Kendzerska; Murray Krahn; Jeffrey C Kwong; Nick Daneman; William Witteman; Nicole Mittmann; Suzanne M Cadarette; Laura Rosella; Beate Sander
Journal:  Am J Gastroenterol       Date:  2015-04-07       Impact factor: 10.864

5.  Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach.

Authors:  Björn Stollenwerk; Thomas Welchowski; Matthias Vogl; Stephanie Stock
Journal:  Eur J Health Econ       Date:  2015-02-04

6.  Direct medical costs attributable to venous thromboembolism among persons hospitalized for major operation: a population-based longitudinal study.

Authors:  Kevin P Cohoon; Cynthia L Leibson; Jeanine E Ransom; Aneel A Ashrani; Myung S Park; Tanya M Petterson; Kirsten Hall Long; Kent R Bailey; John A Heit
Journal:  Surgery       Date:  2015-01-26       Impact factor: 3.982

7.  The economic costs of chronic pain among a cohort of treatment-seeking adolescents in the United States.

Authors:  Cornelius B Groenewald; Bonnie S Essner; Davene Wright; Megan D Fesinmeyer; Tonya M Palermo
Journal:  J Pain       Date:  2014-06-19       Impact factor: 5.820

Review 8.  Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review.

Authors:  Jamison Pike; Scott D Grosse
Journal:  Appl Health Econ Health Policy       Date:  2018-12       Impact factor: 2.561

9.  The economic burden of metastatic breast cancer in Spain.

Authors:  Begoña Bermejo de Las Heras; Javier Cortes Ramon Y Cajal; Elena Galve Calvo; Juan de la Haba Rodriguez; Jesus Garcia Mata; Fernando Moreno Anton; Ignacio Pelaez Fernandez; Alvaro Rodriguez-Lescure; Cesar A Rodriguez Sanchez; Manuel Ruiz-Borrego; Edit Remak; Magdolna Barra; Maria Rivero; Javier Soto Alvarez
Journal:  Eur J Hosp Pharm       Date:  2018-07-30

10.  The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008.

Authors:  Alena Petříková; Tomáš Doležal; Jiří Klimeš; Milan Vocelka; Liliana Sedová; Jozef Kolář
Journal:  Rheumatol Int       Date:  2013-01-13       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.